A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris.

Abstract

In a double-blind, parallel group study we compared fluconazole 150 mg once weekly with griseofulvin 500 mg once daily for 4-6 weeks in the treatment of tinea corporis or tinea cruris. Eighty-four of 114 patients (74%) (39% after 3 weeks) were clinically cured in the fluconazole group compared with 72 of 116 (62%) (39% after 3 weeks) in the griseofulvin group (P = 0.06). In the fluconazole group 78% were mycological cured compared with 80% in the griseofulvin group. In the fluconazole group nine patients (7.5%) had treatment related adverse events and in the griseofulvin group 15 patients (12.5%) had adverse events. Fluconazole 150 mg once weekly for 6 weeks is both clinically and mycologically effective in the treatment of tinea corporis and tinea cruris and few side-effects were reported.

• Authors: J Faergemann, N J Mörk, A Haglund, T Odegård
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 136 Issue 4 Pg. 575-7 (Apr 1997) ISSN: 0007-0963 [Print] England
• PMID: 9155961 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antifungal Agents
• Griseofulvin
• Fluconazole

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antifungal Agents (therapeutic use)
• Double-Blind Method
• Drug Administration Schedule
• Female
• Fluconazole (therapeutic use)
• Griseofulvin (therapeutic use)
• Humans
• Male
• Middle Aged
• Tinea (drug therapy, microbiology)